Oh, what a joyous day for the world of skull base meningiomas! We’ve got a groundbreaking study here, folks, where researchers have taken a stroll down memory lane, looking back at the whopping total of 28 patients who had the pleasure of undergoing stereotactic radiotherapy with HybridArc. These lucky individuals, ranging from sprightly 31-year-olds to wise 83-year-olds, had their brain buddies (tumors, for the uninitiated) zapped with a cozy 54 Gy over 30 fractions. And guess what? They used Novalis STx, because why settle for less when you can have the Cadillac of radiation machines?

Now, hold onto your hats, because the results are just riveting. After a median follow-up of a leisurely 36 months, the tumor control rates were 92.6%, 89.1%, and 82.8% at 1, 2, and 5 years, respectively. But wait, there’s a twist! If your meningioma was of the non-atypical variety, you had a slightly better chance of control—94.1% to be exact. However, if you were in the atypical club, well, let’s just say your numbers weren’t quite as stellar.

And what about side effects, you ask? Only a measly two cases of radiation injury! Plus, a few visual field defects and a dash of diplopia, but some of those even got better, so no biggie, right?

In conclusion, the authors of this little gem would like you to know that zapping your relatively large skull base meningioma with HybridArc is both safe and effective. So, if you’ve got one of those pesky brain tumors, why not give it a try? After all, it’s not like you have a ton of other options.